Comment from Anonymous

Integrated Framework for RT-MSCCS and ARCT ​Regulatory Intent This framework aligns with FDA guidance on "Digital Health Technologies" and "AI/ML-based Software as a Medical Device (SaMD)" to ensure the quality, safety, and scientific validity of clinical trials. By transitioning from traditional, sequential analysis to a real-time, active risk-control model, this system resolves "translational bottlenecks" in research and development, ensuring that patient safety and data integrity remain paramount. ​Challenges and Strategic Solutions To mitigate risks from delayed adverse event detection and inefficient retrospective analysis, we introduce the RT-MSCCS (Real-Time Monitoring, Safety, and Control System). This system establishes continuous oversight, optimizes clinical workflows, and automates administrative burdens, allowing Principal Investigators (PIs) and clinical staff to reallocate their resources toward direct patient care and high-level clinical decision-making. ​System Architecture RT-MSCCS acts as a transparent supervisory layer integrated with Electronic Health Records (EHR) and Real-World Data (RWD) streams. AI Surveillance Layer: Performs 24/7 streaming analysis, conducting anomaly detection by cross-referencing clinical data with real-time patient metrics. Clinical Operations Layer: Accelerates evidence-based interventions via the Automated Decision Support and Governance Workflow (ADSGW). Regulatory Integration Layer: Manages the system lifecycle under a Predetermined Change Control Plan (PCCP), ensuring that all AI algorithm modifications are auditable and compliant. ​Core Control Logic and Risk-Benefit Governance Delta Detection & Concept Drift Monitoring: Monitors real-time changes in data distribution and patient attributes, immediately detecting fluctuations in statistical validity. Risk-Benefit Parity Model: Continuously balances the hazards of clinical intervention against the risks of non-treatment, ensuring an optimal safety-efficacy profile. Dynamic Safety Control: Implements a hierarchical response system: "Adjustment → Warning → Hard Stop." A "Hard Stop" triggers an immediate, mandatory Clinical Override Workflow, requiring verified PI intervention. This mechanism acts as an automated safeguard, ensuring the system never compromises professional clinical autonomy. Manual Ground-Truth Verification: Incorporates periodic audit cycles where human experts review random samples of AI-processed data to calibrate against potential algorithmic blind spots. ​Explainability (XAI) and Accountability AI acts strictly as a decision-support tool, subordinate to the PI's clinical judgment. We implement an Explainable AI (XAI) interface across all processes, visualizing the specific data features that triggered an intervention. The system is equipped with a hard-wired "Fail-Safe" protocol for an immediate, non-negotiable transition to manual control in the event of data inconsistencies. ​Automated Decision Support and Governance Workflow (ADSGW) For critical decision-making, we employ a consensus process that clearly separates automated algorithmic surveillance from human-led governance. This design ensures that the velocity of automation is tempered by human accountability and rigorous professional judgment. The PI maintains ultimate authority; in any conflict between AI output and clinical judgment, human assessment prevails as the definitive standard. ​Regulatory Integration & Data Governance PCCP Strategy: Clearly distinguishes between technical AI tuning and clinical modifications, maintaining compliance via defined threshold-based change management. Data Integrity & Provenance: Adheres to ALCOA+ principles and FHIR standards, with embedded provenance protocols to ensure the absolute reliability of RWD inputs. Cybersecurity: Protects the integrity and confidentiality of RWD through robust threat modeling, strictly adhering to the NIST Cybersecurity Framework (CSF) and relevant FDA Cybersecurity Guidance. ​Implementation & Phasing Phase 1: Observational pilot operations in low-risk trials. Phase 2: Limited integration as a control layer for Adaptive Randomized Clinical Trials (ARCT) with rigorous safety verification. Phase 3: Full-scale operation accompanied by continuous monitoring and periodic reporting to regulatory authorities. ​Expected Outcomes Comprehensive safety assurance through real-time, proactive monitoring. Resolution of "translational bottlenecks" via efficient data filtering and reduced clinical trial cycle times. Reduced PI workload and enhanced, transparent, and auditable regulatory compliance. ​Conclusion The RT-MSCCS/ARCT framework elevates clinical trials into "Real-Time Adaptive Control Systems." By placing risk management, robust governance, and clinical autonomy at the core of the architecture, we establish a new global standard for next-generation clinical research while remaining strictly compliant with FDA standards.